Anna Fabish

Counsel

Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.

pdf

Anna M. Fabish is a litigator whose practice focuses on antitrust issues in complex private civil litigation, regulatory investigations brought by the Federal Trade Commission, and criminal investigations and proceedings against the Department of Justice.

She has represented a variety of domestic and international companies and individuals across the pharmaceutical, healthcare, airline, aeronautics, auto, and technology industries.

VIEW MORE

Languages

  • German

Honors & Awards

  • Fulbright Scholar, Koblenz, Germany

Admissions

Bar Admissions

  • California

Court Admissions

  • US District Court, Central District of California
  • US Court of Appeals, Ninth Circuit

Education

  • Southwestern University, J.D.: summa cum laude; Paul Wildman Scholar; Lead Associate Editor, Southwestern Law Review; Teaching Assistant, Constitutional Law
  • Brandeis University, B.A., German Literature: summa cum laude; Phi Beta Kappa; Presidential Scholar
  • Universitaet Heidelberg, German Academic Exchange Service Scholar, Literature, International and Comparative Law

Professional Activities

Externships

  • The Honorable Arthur L. Alarcón, U.S. Court of Appeals, Ninth Circuit

Speaker

  • “Reverse Payment Settlements: What Lies Ahead,” The Knowledge Group (September 13, 2016) (forthcoming)
  • “Emerging Antitrust Issues: Exploring Reverse Payment Settlements in 2016,” The Knowledge Group (March 11, 2016) 
  • “Demystifying Reverse Payment Settlements in 2015,” The Knowledge Group (June 3, 2015)
  • “Tips and Traps When Working with Economic Experts,” ABA Section of Antitrust Law (November 2014)

Moderator

  • California State Bar Antitrust and Unfair Competition Section, Practical Strategies for Working Efficiently and Effectively with Economic Experts (July 30, 2015)
  • “What the POM Wonderful v. Coca-Cola Decision Does -- and Doesn’t -- Tell Us About the Future of False Advertising Claims Against Food and Beverage Companies” Los Angeles County Bar Association (Sept. 2014)

Author

  • “Considerations, Not Limitations: An Argument against Defining the Anticompetitive Harm under F.T.C. v. Actavis as the ‘Elimination of the Risk of Potential Competition,’” Competition (2016)
  • “REMS Abuse And Antitrust Injury: Round Peg, Square Hole,” Law360 (November 2015)
  • “Why REMS Abuse Doesn't Belong In Antitrust Litigation,” Law360 (2015)
  • “Defense Perspective: Why Associated General Contractors Should Be Used to Assess Standing in Cartwright Act Cases,” Competition (2014)
  • “Pineapples, Presidents and the Federal Courts: A Defense of the Federal Common Law of Foreign Relations and a New Framework for Its Application,” 35 Sw. Univ. L. Rev. 253

Co-Author

  • “Federal Trade Commission Statements Regarding First FTC Settlement Of Reverse Payment Claims Post-Actavis and Largest Ever Disgorgement Award,” (June 2015)
  • “Drafting Pharmaceutical Patent Settlements with ‘Actavis’ in Mind,” Corporate Disputes (April/June 2015)
  • “New Frontiers in Pharmaceutical Antitrust,” Course Materials for ABA Antitrust Section’s 63rd Annual Spring Meeting, Panel Presentation
  • “Beyond Reverse Payments: The New Frontiers in Pharmaceutical Antitrust” (April 14-17, 2015)

Member

  • Former Chair (2015-2016), Vice Chair (2014-2015), and Secretary (2013-2014), Antitrust and Unfair Business Practices Sections of the LA County Bar Association
  • Antitrust and Unfair Competition Section Executive Committee, California State Bar
  • Representing drug manufacturer in enforcement action brought by Federal Trade Commission involving alleged “reverse payment settlements” 
  • Representing drug manufacturer in Federal Trade Commission investigations involving alleged “reverse payment settlements”
  • Defending drug manufacturer in MDL class actions against claims brought under federal and state antitrust laws by direct and indirect purchasers alleging improper “reverse payment settlements”
  • Representing foreign auto part manufacturer in DOJ investigation regarding price-fixing allegations and related private civil suits
  • Defending leading U.S. airline in private civil suit alleging price-fixing conspiracy
VIEW MORE